Day One Biopharmaceuticals (NASDAQ:DAWN) Downgraded by Zacks Research to “Hold”

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also commented on DAWN. Needham & Company LLC lowered their price target on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. Piper Sandler boosted their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright decreased their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, TD Cowen began coverage on Day One Biopharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $26.14.

Day One Biopharmaceuticals Trading Down 2.6%

Shares of NASDAQ DAWN opened at $10.65 on Wednesday. The stock’s 50-day moving average is $10.69 and its 200 day moving average is $8.77. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -10.34 and a beta of -1.26. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The firm had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. On average, analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity

In other Day One Biopharmaceuticals news, insider Michael Vasconcelles sold 2,728 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the transaction, the insider owned 4,397 shares in the company, valued at approximately $51,005.20. This represents a 38.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Adam Dubow sold 6,395 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider directly owned 72,694 shares in the company, valued at approximately $843,250.40. The trade was a 8.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 36,461 shares of company stock valued at $422,948. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. Rubric Capital Management LP purchased a new stake in Day One Biopharmaceuticals in the third quarter worth approximately $23,808,000. Vestal Point Capital LP lifted its holdings in shares of Day One Biopharmaceuticals by 94.4% during the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after buying an additional 2,525,000 shares during the period. AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $10,719,000. Mak Capital One LLC purchased a new position in Day One Biopharmaceuticals in the third quarter worth about $10,212,000. Finally, Balyasny Asset Management L.P. bought a new stake in Day One Biopharmaceuticals during the third quarter valued at approximately $9,758,000. Institutional investors own 87.95% of the company’s stock.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.